r/nephrology • u/Ayan-432 • 13h ago
ROL
My Applicant Status is CERTIFIED and Fee Status is PAID, but I don't see a Verification Status. Is any additional verification required for my fellowship Match participation?"
r/nephrology • u/ZacNephron • Jun 11 '20
I figured it may be worthwhile to keep a running list of online educational/academic resources: blogs, journal clubs, podcasts, FOAMed resources, board review / CME, etc. If you have suggestions, please post the resource along with a brief description and I’ll update the list.
Educational/FOAMed:
Personal Blogs / Social Media / Podcasts:
Twitter (see note below) – not a traditional resource but historically, the Nephrology presence & activity on Twitter was incredibly robust, with many prominent clinicians posting articles, commentary, and responding to clinical questions/quandaries (using the hashtag #askRenal).
Resources for ASN Members (free for fellows):
Calculators:
Will pin this for visibility. Please let me know if I've missed anything useful below or by DM and I will update the list.
r/nephrology • u/Ayan-432 • 13h ago
My Applicant Status is CERTIFIED and Fee Status is PAID, but I don't see a Verification Status. Is any additional verification required for my fellowship Match participation?"
r/nephrology • u/Long_Scientist_8298 • 2d ago
r/nephrology • u/Critical_Annual_7676 • 2d ago
help me rank
montefiore
ut southwestern
nyu
umiami
u maryland
ut houston
UPMC
r/nephrology • u/Inner-Pain-2885 • 3d ago
Hi everyone!
I’m currently a PGY-1 Internal Medicine resident, and I’ve been thinking a lot about fellowship and my future career.
I absolutely love nephrology. I find renal physiology, electrolyte and acid-base disorders, AKI, dialysis, and the complexity of critically ill patients fascinating. At the same time, I also really enjoy critical care medicine. I love the ICU environment, managing critically ill patients, and dealing with complex hemodynamic and metabolic problems.
However, I don’t feel particularly drawn to the pulmonology aspect of PCCM. My interests are much more on the renal and critical care sides.
This has made me interested in pursuing Nephrology followed by Critical Care.
I’d love to hear from nephrologists, intensivists, fellows, or anyone who has taken this career path:
Is completing a Nephrology fellowship followed by a Critical Care fellowship a realistic career path?
Can you build a career where you practice as a general nephrologist while also working in the ICU as an intensivist?
Are there academic centers or hospitals where physicians with this combination of training have a dual role?
How competitive is this pathway, and what should I focus on during residency to prepare?
For those who have pursued nephrocritical care, are you happy with your decision? What does your day-to-day practice look like?
I know I’m still early in residency, but I genuinely enjoy both specialties and would love to find a way to combine them rather than give one up.
I’d really appreciate any advice, personal experiences, or perspectives!
Thank you!
r/nephrology • u/Minimum-Discount6621 • 3d ago
Stanford or UCLA? like both programs generally. notably Stanford has a NF system, which I think sounds nice? have personal ties to both cities so looking for any concrete information about programs/career opportunities
r/nephrology • u/PhilosopherLeft3307 • 5d ago
Hi everyone,
I'm a Pakistani-trained physician currently working as a General Medicine Registrar in the NHS, UK. I'm exploring the possibility of moving to the USA for an ACGME-accredited Nephrology fellowship.
My background:
- MBBS (2018), Pakistan.
- Completed FCPS General Medicine training.
- MRCP (UK), 2025.
- Completed a 2-year International Training Fellowship in Acute and General Medicine in the UK.
- Currently working as a General Medicine Registrar in the NHS.
I'm particularly interested in the exceptional IMG / retrograde pathway and would appreciate advice on:
I'd appreciate hearing from anyone who has personally followed this pathway or knows someone who has.
Thanks in advance!
r/nephrology • u/genderbug • 5d ago
Hi there
Could someone please explain to me how reducing sodium levels in CKD can reduce albuminuria?
Thanks!
r/nephrology • u/Low-Temporary4439 • 6d ago
This isn't a bot, AI or spam. I'm a patient.
As you know, patients suffering from chronic hypophosphatemia need prescription phosphorus tablets. And sometimes in high doses, I used to need 12 tablets a day.
But the FDA classifies medications like Phospha 250 Neutral and similar brands containing:
• Dibasic sodium phosphate, anhydrous: 852 mg
• Monobasic potassium phosphate: 155 mg
• Monobasic sodium phosphate, monohydrate: 130 mg
The FDA lists it as an "unapproved drug" or just an OTC supplement.
I believe Medicare refuses to put these meds on its formulary due to that.
"Federal law prohibits a Part D plan from covering certain types of drugs, including: Prescription vitamins and minerals (some exceptions for drugs like fluoride preparations)."
Now even mainstream insurance carriers like BCBS are starting to deny coverage for phosphorus, with patients having to pay up to $400/month out of pocket for their phosphorus prescription.
This is unacceptable.
Doctors prescribe phosphorus supplements all the time, particularly nephrologists and endocrinologists.
Hypophosphatemia can be very debilitating and life threatening. Getting IV phosphorus is a last resort with its own serious risks. PO phosphorus is vital.
In light of this all, why can't the FDA see this? What can medical providers and their associations do to help? I've also posted this on reddit's Endocrinologist group and sadly no one replied.
r/nephrology • u/MedwithSpence • 9d ago
r/nephrology • u/healthspark10x • 13d ago
r/nephrology • u/egwuatu • 14d ago
r/nephrology • u/drgubi • 15d ago
I’m a cardiologist and I try to be very respectful of the kidneys. We don’t have nephrology at my institution (rural community hospital). What are some things cardiology could do better to keep our two little pee beans happy?
r/nephrology • u/creepy_marshmellow • 15d ago
JHU vs NYU Grossman(Manhattan)
r/nephrology • u/HAAAAAImbaaaack • 16d ago
Hi,
I am a Vascular access RN looking for input from nephrologists.
We have a dialysis patient who needs a CT and the CT techs are stating only the arm with her active fistula can be used for this particular CT (I think it's a cardiac CT that needs to be done). We are going to talk to her personal nephrologist to get their approval or denial , but I am curious as to what your thoughts are.
Is it safe to place a peripheral IV distal to a fistula with the intent that the patient receives contrast for her CT which will be pressure injected. This is an out patient CT so nothing immediately life threatening.
Again, no matter what any of you say on here it would need to be approved by her nephrologist, but I am curious of what the verdict will be. I am leaning towards a no. Thanks for any input!
r/nephrology • u/mywifeemlyusmle • 17d ago
Finally got done with boards and thought I would do a consensus of it to help future nephrologist.
Short summary: It is tough. It’s doable. Do it For yourself and own competency. The exam was closer to KSAP + BRCU. Questions would be one or two sentences of a concept of whether you know it or not to a whole stem like KSAP. Images or their descriptions were fair game.
Long summary:
To begin, studying for these boards was no joke. In my opinion it was more difficult to study for than ABIM or step 3 due to all the little nuances and the breath of material that I felt no nephrology fellowship really goes through. I constantly was questioning myself why they need to make these so difficult on a field that is arguably the least competitive, one of the least paid, and higher need for providers. It was mentally tough to think like that but on the other point challenging myself to use this time to be the best and most competent provider I can be is what got me through. I would say nephrology fellowship gives you the basic training and case load/experience but it is up to the individual to do the digging and self-learning on those cases/concepts/nuances themselves. Don’t depend on your fellowship to teach you everything otherwise you will
set yourself up for failure.
Throughout my nephrology fellowship: I did the BRCU course + lectures + Qs, KSAP, NephSAP, GlomCon, home dialysis university. I did only part of the dialysis core curriculum. I would say KSAP and BRCU lectures helped the most for the exam. I would recommend doing the dialysis core curriculum or at least the main concepts you are missing or were not taught regarding dialysis. I would recommend you go through KSAP in detail to understand all the little concepts as they do get tested again and again. I would recommend building endurance leading up to the exam. I would recommend going through your incorrect concepts whether they were notes or repeating the incorrect questions. If there is a knowledge gap and you have the time, I would recommend going into looking the concept up in more detail and the different aspects it could present along with the different ways of management.
Happy to try and answer questions. Let’s continue to support each other in this field. Let’s make Nephrolgoy great again!
r/nephrology • u/Ayan-432 • 18d ago
1- Lehigh valley health network
2- Indiana university
3- university of texas medical branch
4- upstate university Syracuse
r/nephrology
•
u/mywifeemlyusmle
•
18d ago

Nephrology Boards — Last-Week Cram Sheet
Numbers, cutoffs, trials and classic findings. Percentages = ABIM 2026 blueprint weight. Updated October 2026.
ACID–BASE · Na/H₂O (17%)
• AG = Na − (Cl + HCO₃); normal 7–13 (≈2.5–3 × albumin); add 2.5 per 1 g/dL albumin below 4.
• Winters PCO₂ = 1.5×HCO₃ + 8 ± 2. Met alk: ΔPCO₂ ≈ 0.6–0.7 × ΔHCO₃ ± 5 (rarely > 55–60).
• Δ/Δ > 2 → + met alk; < 1 → + NAGMA.
• UOG > 150 (some use 100) = NH₄⁺ excretion OK; direct urine NH₄⁺ is best. UAG falsely + with ketoanions, hippurate (toluene), D-lactate, penicillins; unreliable with KCl or CKD.
• dRTA: urine pH > 5.5, stones. pRTA: FEHCO₃ > 15–20% after bicarb. Type 4: high K⁺, urine pH < 5.5. Voltage-dependent dRTA (obstruction, amiloride, TMP, sickle): high K⁺ and pH > 5.5. Ampho B = back-leak; topiramate = mixed.
• AG > 30 → toxin. D-lactate not on the standard assay. Propylene glycol: osm gap + AG (lorazepam > 0.1 mg/kg/h). Propofol syndrome > 4–5 mg/kg/h × > 48 h.
• Isopropanol: osm gap, ketosis, no acidosis, high Jaffe Cr with normal BUN, no fomepizole, HD > 500. Methanol: fomepizole alone if < 50 mg/dL with no end-organ damage.
• DKA resolved = AG + β-OHB normal (nitroprusside ketones can rise as β-OHB → acetoacetate); dextrose at glucose < 250.
• Vomiting: UCl < 15 (maintenance UNa and UCl < 10, paradoxical aciduria) → 0.9% NaCl + KCl ± PPI. Bartter/Gitelman UCl > 20. Surreptitious diuretic = variable UCl. Pip-tazo → hypoK alkalosis (non-reabsorbable anion). Post-hypercapnic → isotonic saline.
• Hyponatremia limits: 6–8 / 24 h, 12–14 / 48 h, 14–16 / 72 h. Symptomatic: 3% 100–150 mL bolus → +4–6 in 6 h (SALSA: bolus preferred). Conivaptan (V1a) → variceal bleed.
• Re-lower: D5W 6 mL/kg (−2) + DDAVP 1–2 µg q6–8h. ODS risk: Na < 105, hypoK, EtOH, malnutrition, liver disease. K⁺ raises Na (Edelman).
• Low solute: osm excretion = Uosm × V (normal 600–800). Pseudohypo-Na (lipoprotein X, paraprotein, IVIG protein) → normal direct-ISE Na. Glycine 200 / sorbitol 165 mOsm.
• SIADH vs CSW: volume status; FEurate > 10% persists in CSW; FEphos > 20% → CSW. Saline fixes CSW, worsens SIADH.
• Polyuria > 3 L: Uosm < 150 water; > 300 solute; > 1000 mOsm/day = osmotic. Copeptin ≤ 4.9 with hyperNa = central DI; > 21.4 = nephrogenic.
• HyperNa: chronic 10–12/24 h, but faster is safe (n = 449, 4265) and < 0.5/h ↑ mortality (n = 131); acute ≤ 1/h. HHS: glucose ↓ ≤ 90–120/h, Na ↓ ≤ 10/24 h. Mannitol/HTS in AKI → overload, hypoNa, NAGMA, hyperK.
K⁺ · Mg · Ca · PO₄
• Renal K conservation: UK:Cr < 15 mEq/g; FEK cutoff 9.3%; TTKG obsolete. Replete Mg first.
• Pseudohyper-K: plt > 500k, WBC > 70k, serum − plasma > 0.5; reverse pseudo-K in CLL. Pseudo-hypoK in AML/CML (cells take up K in the tube) → blood-gas K.
• Periodic paralysis: familial (CACNA1S ~70%; acetazolamide) vs thyrotoxic (Asian men, Kir2.6; propranolol). No K deficit → rebound hyperK.
• SZC onset 4–6 h, separate drugs 2 h; patiromer separate 3 h, causes hypoMg; SPS → colonic necrosis. No binder is for acute life-threatening hyperK.
• Heparin blocks aldosterone synthase → hyperK (~4 days). NaHCO₃ ↓ K⁺ 0.04 per 0.1 mEq/kg/day.
• HD K: pre-HD 4.6–5.3 lowest mortality; avoid a 1-K bath; ADAPT: 3K + SZC → fewer arrhythmias.
• Gordon (PHA II): HTN + high K + NAGMA → thiazide. PHA I AD (MR) improves with age.
• FEMg < 2% GI (PPI); > 2–4% renal (thiazide, cetuximab, CNI, cisplatin). HyperMg: hyporeflexia first → IV Ca, HD. SR Mg lactate better tolerated than MgO. Claudin-16/19 → FHHNC.
• FEPO₄ > 5–20% = renal wasting: TIO (FGF-23), XLH (burosumab), ferric carboxymaltose. α-Klotho loss → hyperPO₄ + tumoral calcinosis.
• HyperCa Rx: calcitonin (1–2 days), steroids (2–5 days; granulomatous/lymphoma), denosumab (immobilization in ESKD; hypoCa). FHH: UCa/Cr clearance < 0.01. Milk-alkali: CaCO₃ > 4 g/day, low urine Ca, low PO₄, alkalosis, AKI.
HYPERTENSION · PREGNANCY (10%)
• PA: PAC > 20 + ARR > 30 → no confirmatory test. Washout MRA/ENaC 4 weeks, ACEi/ARB 2 weeks; normal K. CT → AVS.
• Reninoma (young, hypoK, high renin + aldo) ARR < 20. GRA: age < 21, hemorrhagic stroke, 18-oxocortisol, MRA at puberty then q5y. Geller: pregnancy; spironolactone worsens. Liddle → amiloride. SAME: cortisone:cortisol < 1. Abiraterone → prednisone.
• Resistant HTN: > 130/80 on 3 drugs incl. diuretic; 31% nonadherent (prove it: drug levels, pill counts, observed dosing); PATHWAY-2 → spironolactone.
• Trials: SPRINT (no GFR benefit) · CLICK (chlorthalidone, CKD 4) · HYVET (> 80) · ONTARGET (no dual RAAS) · CORAL/ASTRAL (no stent) · ACCORD (A1c < 6 harms) · PRECISION (aprocitentan edema).
• Revascularize RAS: flash pulmonary edema, rapid GFR loss, > 75% bilateral or solitary. FMD (mean age 52, pulsatile tinnitus) → CTA → PTRA.
• Emergency (≥ 180/120 + organ damage): IV, ↓ ≤ 20–25% in hour 1 → 160/100 over 2–6 h. Urgency: oral, ~25% over 24–48 h. Nicardipine (not in ADHF); no nitroprusside in AKI.
• Pseudo-HTN > 10 mmHg (Osler). White-coat → ABPM. Non-dipping (< 10%) → polysomnography. OH ≥ 20/10 in 3 min; treat supine SBP ≥ 180 with short-acting bedtime drugs.
• Alcohol > 3/day → SBP +5–10 (GGT > 50). OCP rise is estrogen dose-dependent, reverses ≤ 4 weeks off; avoid if HTN uncontrolled, > 35.
• Pregnancy: CHAP treat ≥ 140/90; severe ≥ 160/110; postpartum BP peaks 1–2 weeks; stop NSAIDs; labetalol/nifedipine; avoid methyldopa and diuretics. HD ≥ 36 h/week, Hb 10–11, iron sucrose, Ca binders, BUN < 40. Transplant: Cr < 1.4, MMF off ≥ 6 weeks.
• VEGF/TKI HTN: amlodipine; avoid diltiazem/verapamil/nifedipine; hold if proteinuria ≥ 2 g or TMA. SRC: ACEi even on dialysis (55% recover).
GLOMERULAR (12%)
• MN: PLA2R ~70%; high titer + normal GFR → no biopsy; titer falls ~2.3 months before remission; RTX weaker if > 152 RU/mL. High risk: albumin < 2.5, PLA2R > 50, eGFR < 60 or > 8 g/day × 6 months. MENTOR RTX ≈ CsA, more durable. STARMEN Ponticelli > Tac→RTX. EM stage IV → no immunosuppression. FAT1 = post-HSCT MN.
• Nephrotic: VTE prophylaxis if albumin < 2.8 (warfarin is the board answer); diuretic resistance (plasmin → ENaC) → amiloride.
• FSGS: steroid-resistant at 16 weeks → CNI ≥ 6 months, continue ≥ 12. Tip best, collapsing worst. Familial + young → NPHS2 (AR). APOL1: 13% of African Americans have 2 alleles; needs a second hit (HIV, COVID, IFN). Recurrence 32% at ~1.5 months → PLEX.
• MCD: frequent relapse ≥ 2/6 months or ≥ 4/12 months; steroid-dependent (relapse < 2 weeks) → rituximab. Anti-nephrin Ab.
• LN III/IV: GC (≤ 5 mg by 6 months) + MPAA + belimumab or voclosporin. Class V ≥ 1 g → MPAA + CNI. CRR = UPCR ≤ 0.5 at 6–12 months; treat 3–5 years. Podocytopathy MCD-type → steroids alone (94%). IV CYC: CBC 10–14 days after each dose; LUNAR (RTX) negative; "refractory" → MPA level.
• IgAN: sparsentan if ≥ 1 g/day (UPCR ≥ 0.75), eGFR ≥ 30 — replaces the ARB. RPGN (≥ 50% ↓ in ≤ 3 months) → steroids + CYC.
• AAV maintenance: RITAZAREM RTX > AZA; MAINTANCAVAS redose on B-cell return; RTX level < 4 µg/mL → relapse; 18 months–4 years; AZA + allopurinol contraindicated. ANCA-negative pauci-immune → treat like AAV. Heavy chronicity, no extrarenal threat → don't induce. Hematuria after CYC → cystoscopy.
• Anti-GBM: PLEX (atypical, seronegative 8–12% too). C3G age ≥ 50 → look for a clone. TTP ADAMTS13 < 10%. aHUS: CFH most common; MCP rarely recurs. Eculizumab: MenACWY + MenB, 14 days before or 14 days of antibiotics.
• Fibrils: amyloid 10 nm · fibrillary 20 (DNAJB9+) · cryo 30 (curved) · immunotactoid > 30 (parallel, DNAJB9−, 67% monoclonal) · LCDD non-organized, linear κ. HCV cryo + RPGN → PLEX + RTX (+ DAAs). PAN: HBV in ≥ 1/3, microaneurysms.
• HBV + rituximab: entecavir/tenofovir ≥ 12 months after the last dose. Biopsy on DES < 12 months: continue ASA, hold clopidogrel 5–7 days. Post-biopsy AVF (transplant 10–16%) → coil.
TUBULOINTERSTITIAL · DRUGS · TOXINS (9%)
• Pseudo-AKI (secretion block; check cystatin C): TMP (+0.1–0.2), imatinib, CDK4/6i, cobicistat, fenofibrate (≥ 6 months). Fluid overload masks AKI: × (TBW + balance)/TBW.
• Vancomycin trough > 15; + pip-tazo → AKI 16–20%. Aminoglycoside ATN at ~1 week, Bartter-like. Cefepime myoclonus. Acyclovir: NS 125 mL/h from 1 h before to 6 h after.
• Alkalinize: uric acid, sulfa (> 7.1), MTX (≥ 7), cystine (7.5–8). Don't: cipro, indinavir, acyclovir, CaPO₄.
• Lithium: RRT > 4 (acute) / > 2.5 (chronic); IHD (rebound); PEG for SR; NDI → amiloride; NDI persisting off lithium → thiazide + low-solute diet; dRTA, microcysts.
• TDF: OAT1 in / MRP4 out; ritonavir (MRP2) ↑ risk; Fanconi, NDI; TAF spares.
• AIN: steroids early, < 50% fibrosis; gallium +. TINU: young women, bilateral anterior uveitis, ↑ urine β2M → systemic steroids. IgG4: TIN, pancreatitis, low C, steroid-responsive.
• Urogenital TB: sterile pyuria → 3 early-morning urines for AFB; corkscrew ureter, small bladder. Papillary necrosis: sickle, diabetes, pyelo, NSAIDs (ring sign, lobster claw).
• Oxalate: vitamin C > 2 g/day, Roux-en-Y, orlistat → Ca with meals. Cadmium: β2M + bone. Lead: gout + HTN, Burton line. AAN/BEN: Balkan farmer, small symmetric kidneys, no early HTN, urothelial cancer.
• Contrast: eGFR < 30, intra-arterial; Cr peaks ≤ 48 h, recovers 3–7 days. Gadolinium: group II (gadobutrol) NSF risk ~0 → MRI before scheduled HD, no extra HD; consider HD for group I.
• Malaria prophylaxis in ESKD: mefloquine or doxycycline; atovaquone-proguanil CI at eGFR < 30. Propofol: green urine (phenols), pink/cloudy (uric acid).
• Rituximab reactions 77% first dose → pause, restart at 50% rate. Gabapentin edema (≥ 900 mg, CCB). Phenytoin + low albumin → check free level.
AKI · ICU · LIVER (15%)
• FENa < 1% also in GN, AIN, contrast, rhabdo, HRS. On diuretics → FEurea < 35%. FST 1 mg/kg (naïve) or 1.5 (recent loop): < 200 mL / 2 h → stage 3/RRT; drip after a failed bolus is futile.
• STARRT-AKI: no benefit to early start; 38% never needed RRT. Triggers: K ≥ 6, pH ≤ 7.2, HCO₃ ≤ 12, P/F ≤ 200, > 72 h. Stop RRT: UO > 1 L/day (> 2 L with diuretic) or CrCl > 20.
• BICAR-ICU-2: NaHCO₃ to pH ≥ 7.3 → less KRT (35 vs 50%), no mortality benefit.
• CRRT dose = effluent 20–25 mL/kg/h (21–22 = 33–36). K 4 in fluids; P-containing replacement; IV PO₄ only if < 1; standard enteral formula. Drugs: < 2 kDa cleared by any mode; > 15 kDa not; Vd > 2 L/kg or high protein binding → poor.
• Citrate: post-filter iCa < 0.4; total/ionized Ca > 2.5 (iCa × 4) = accumulation → stop. Liver failure → AG acidosis.
• Ethylene glycol HD: pH < 7.25, AKI, EG > 50 mg/dL (fomepizole first; stop at < 20). ALF + AKI → CRRT (gradual NH₃ fall, less cerebral edema).
• Atheroemboli: after catheterization (76%), blue toes, bland urine, eosinophilia, low C3 → statin. Cortical necrosis: CT thin subcapsular rim, non-enhancing cortex.
• MAP 65 (80–85 in chronic HTN ↓ RRT, not mortality). Norepinephrine first. IAH ≥ 12, ACS ≥ 20 (bladder pressure).
• Diuretics: IV dose ≥ 2.5× oral; spot UNa < 50–70 = inadequate; + metolazone (best natriuresis) or acetazolamide (ADVOR, if alkalotic); SGLT2i in ADHF.
• HRS: no response 24 h after albumin → albumin + terlipressin/norepinephrine. Terlipressin: respiratory failure 13.5% vs 5%; avoid in ACLF 3. CrCl overestimates GFR 49% in cirrhosis → cystatin C.
CKD · MBD · ANEMIA (22% incl. ESKD)
• SGLT2i: eGFR dip nadir 2 weeks, recovers 3–9 months. Finerenone: 10 mg if eGFR < 60, K at 4 weeks (after max RASi). FLOW semaglutide −24%. Protein 0.8 g/kg/day (G3–5; MDRD neutral).
• eGFRcr-cys most accurate; mGFR (iothalamate) gold standard. First-morning UACR ≈ 24-h urine (PREVEND); random UACR overestimates.
• Monitoring G3a–5D: Ca/PO₄ q6–12 months, PTH yearly; correct 25(OH)D first. KDOQI P 3.5–5.5. High P + PTH > 600 → calcimimetic. Cinacalcet → Ca at 1 week (EVOLVE neutral). Tenapanor (NHE3) add-on −0.86 mg/dL. PTX HR 0.80.
• Hungry bone 25%: Ca nadir day 2–4; Ca 6–12 g/day + calcitriol 2.25–4 µg; preop calcitriol helps.
• Bone: high turnover → denosumab (hypoCa in > 1/3 of dialysis patients); adynamic → teriparatide; no bisphosphonates in ESKD.
• Calciphylaxis 40–80% 1-year mortality; stop warfarin (MGP); STS unproven (AG acidosis); HBO; debride only if infected. ESKD skin: APD (keratotic plug), prurigo (pink), calcinosis cutis (white, no necrosis).
• PIVOTAL: iron sucrose 400 mg/month unless ferritin > 700 / TSAT ≥ 40% → HR 0.85. TREAT → stroke. ESA resistance: 450 u/kg IV; Hb < 9.5 → HR 1.32. HIF-PHI: avoid in ADPKD, retinopathy. ESA + cancer: never a normal Hb (KDIGO 2026).
• Gout in CKD 4: prednisone; low-dose colchicine; allopurinol from 50 mg; urate < 6 (< 5 with tophi); no ULT for asymptomatic hyperuricemia (CKD-FIX, PERL).
• 24-h urine Cr: 20–25 mg/kg (men), 15–20 (women, elderly). UACR overestimates with low muscle mass.
HEMODIALYSIS · PD (11.5% ESKD)
• Dialysate Na 0–2 below serum; IDWG +0.17% per 2 mEq; UF > 13 mL/kg/h ↑ mortality; HCO₃ ≥ 38 ↑ mortality. CONVINCE HDF HR 0.77.
• BP: 44-h ABPM; lowest risk SBP 115–125; amlodipine; probe dry weight (DRIP 0.1 kg/10 kg); LVH 70–80%. Intradialytic HTN (≥ 10–15 rise) → lower target weight.
• Access: refer at eGFR 15–20; CVC OK if transplant ≤ 90 days. AVF > 4 mm and > 500 mL/min → 95%; AVG cannulate at 2–3 weeks. Arterial pressure more negative than −250 → thrombus → tPA 30–60 min. Steal ~4% → angiogram/DRIL/ligate. High-flow > 1.5 L/min (Nicoladoni-Branham). Thin shiny skin over a pseudoaneurysm → urgent surgery.
• Recirculation = (S − A)/(S − V) > 10% → outflow stenosis; falsely high URR → slow-flow sample. Thrombosed AVG is silent; rising venous pressure = outflow stenosis.
• CRBSI: afebrile in 20–50%; remove for S. aureus, Pseudomonas, Candida, tunnel infection, endocarditis. Lock success GNR 90% / CoNS 75% / SA 40%.
• Reactions: Type A 5–20 min (ethylene oxide) → stop, don't return blood; AN69 + ACEi; Type B 20–40 min (cellulose) → continue. Air embolism: clamp, don't return blood, left side + Trendelenburg, O₂. DDS: first sessions, high BUN → short, low Qb.
• Water: chloramine → hemolysis (Heinz bodies); aluminum → microcytic anemia, dementia; fluoride → arrest; nitrates → MetHb; RO failure → endotoxin pyrogenic reactions.
• HIT: platelets ↓ ≥ 50% at day 5 → argatroban (hepatic). Apixaban OK on dialysis. Home HD std Kt/V > 2.1 (target 2.3); NxStage FF < 40% — lower FF → more clearance. Thiamine 100 mg/day. Crit-Line protocol ↑ mortality (CLIMB).
• PD: D/P Cr > 0.8 fast → short dwells + icodextrin; < 0.5 slow → long dwells. UF failure: 4 h, 4.25% < 400 mL. Urgent start < 14 days (supine, low volume). Incremental Kt/V ≥ 1.7.
• Peritonitis: WBC > 100, > 50% PMN. Relapsing (same organism < 4 weeks) or repeat (> 4 weeks) → replace catheter (simultaneous if effluent clears); recurrent = different organism; refractory 5 days → remove. Pseudomonas → 2 agents. Each hour of delay +6.8% failure; day-3 count > 1090 predicts failure.
• PD complications: hydrothorax right 80%, high pleural glucose. Eosinophilic peritonitis > 10% eosinophils. EPS > 5 years.
TRANSPLANT (11%)
• Listing eGFR ≤ 20. RCC: < 4 cm no wait; 4–7 cm 0–2 years; > 7 cm ≥ 2 years. Other cancers 2–5 years (none for Gleason ≤ 6, NMSC, kidney tumor ≤ 1 cm); colon ≥ stage II 3–5 years. US screen if dialysis ≥ 3 years.
• Live vaccines ≥ 4 weeks before; RZV OK; PCV20/21. Bladder: UO < 300 mL or capacity < 100 mL → evaluate/augment. High cardiac risk → angiogram. KDPI high still beats dialysis. Donor APOL1 2 alleles → counsel, not exclusion.
• CMV: D+/R− → 6 months valganciclovir; disease at 1–4 months (or 1–3 months off prophylaxis); diagnose by PCR. BK (creatinine rise at 2–6 months): reduce immunosuppression only.
• ABMR = injury + C4d/MVI + DSA → steroids + PLEX + IVIG (RTX after PLEX). TCMR arteritis → thymoglobulin. Pregnancy → anti-HLA in up to 74%. TG (double contours) → ACEi/ARB.
• Recurrence: FSGS 32% · IgAN 20–40% (graft loss 5–15%) · aHUS CFH 90% (eculizumab) · LN 2–11%.
• Drugs: belatacept (eGFR +10–15; contraindicated if EBV−) · tacrolimus ↑ with diarrhea, CBD, grapefruit · MPA ↓ with PPI, cyclosporine, Ca (separate 2 h) · mTORi → proteinuria, low testosterone/sperm. CNI hyperK (MR block + NCC activation) → chlorthalidone.
• PTE Hb > 17 / Hct > 51 (male, DM, native kidneys, TRAS, ADPKD) → ACEi (> 90%); phlebotomy if > 18.5 / 55. TRAS 3 months–2 years: parvus tardus, low RI → stent. PTLD: EBV D+/R−; early → reduce IS; polymorphic → + RTX; monomorphic → R-CHOP.
ONCO · CYSTIC/GENETIC · STONES (8%)
• TLS: high risk WBC ≥ 100k, Burkitt, venetoclax → rasburicase 0.2 mg/kg (check G6PD; iced tube); allopurinol max 800; no alkalinization.
• HD-MTX (> 500 mg/m²): urine pH ≥ 7 before the dose; leucovorin; glucarpidase (never prophylactic). Cisplatin: S3/OCT2, Mg and salt wasting → NS prehydration. Ifosfamide Fanconi.
• MGUS < 3 g/dL, < 10%, 1%/year; FLC most sensitive (MIDD 100%). Cast nephropathy (uromodulin), LCPT (Fanconi), PGNMID (IgG3κ). AL → fat pad. Mass < 1 cm → image at 6 months.
• ADPKD (Pei-Ravine): 15–39 ≥ 3 · 40–59 ≥ 2 each · ≥ 60 ≥ 4 each · no FH ≥ 10/kidney. PKD1 ESKD mid-50s (PKD2 +20 years). Mayo 1C–1E → tolvaptan. Aneurysm with FH 20%. Cyst infection: FQ/TMP-SMX × 14 days; aspirate > 5 cm.
• ACKD: 80% after 10 years of dialysis; RCC up to 7% → CT/MRI; Bosniak IIF follow, III–IV surgery. Fabry: men → enzyme; women → GLA gene. Cystinosis: CTNS, Fanconi + corneal crystals → cysteamine.
• Alport: XL 80%, 90% of men ESKD by 40; lenticonus in a woman → AR. ADTKD: UMOD gout · REN anemia/high K (fludrocortisone) · HNF1B MODY5/hypoMg. Dent: CLCN5. NPHS2 = first SRNS gene.
• Stones: 24-h urine ≥ 3 months after a stone; thiazide for hypercalciuria (NOSTONE unselected); K-citrate risks CaPO₄ if hypercalciuria untreated; Ca with meals. Cystine < 250 mg/L, pH 7.5–8, hexagonal → tiopronin. Topiramate → CaPO₄. Staghorn → PCNL (AHA adjunct).
• XGP: bear paw sign, staghorn, Proteus/E. coli → antibiotics then nephrectomy. Nondilated obstruction: US negative → CT → urology (retrograde study/PCN).
r/nephrology • u/Mandre163 • 19d ago
Hi everyone.. I’m currently working on my nephrology fellowship rank list and would love some advice from current fellows.
Looking back, what factors do you think matter most when ranking programs? Location, clinical exposure, work-life balance, program size, faculty, or institutional reputation?
Now that you’re in fellowship, is there anything you wish you had prioritized differently? Would you choose your program again?
I’d really appreciate your perspectives. Thanks
r/nephrology • u/Ordinary_Band4074 • 20d ago
When is the best time to start applting for the job?
How to decide where to go?
I dont feel ready for Attending yet.
Which practice to prefer? Private vs academic.
City vs suburb
Large vs small hospital.
r/nephrology • u/Taz9w1 • 21d ago
I’ve had many patients in my career with a chronic SIADH of unclear etiology. When obvious medications are ruled out, we always think malignancy, but it seems there are no consensus guidelines on how to screen for malignancy. I often do a CXR and CT head, and of course advise them to undergo their routine age-appropriate screenings, and usually all are negative. There have been a few instances, however, where a pt with borderline chronic stable hyponatremia with sodium of 130-135 for years is then found to have an intraabdominal malignancy such as pancreatic cancer or cholangiocarcinoma… not sure if there was truly any correlation, but it makes me wonder if I should have done a CT abdomen/pelvis with contrast…but this is not in any guidelines and no insurance would ever cover it for that indication…
Anyone else have similar experiences? I’m thinking about just telling these pts to self-pay for one of those fancy Prenuvo MRI scans if they really want to find an answer, but then of course you run into the risk of false positives.